A Single-centre Phase III Clinical Trial for Vero Cell-derived Inactivated Japanese Encephalitis Vaccine Produced by Shandong Hengye Biotech Co., Ltd. in Healthy Chinese Infants Aged 6-11 Months, Aimed to Evaluate Immunogenicity and Safety
Phase of Trial: Phase III
Latest Information Update: 14 Sep 2016
At a glance
- Drugs Japanese encephalitis vaccine (Primary)
- Indications Japanese encephalitis
- Focus Adverse reactions; Pharmacodynamics; Registrational
- 30 Aug 2016 Status changed from active, no longer recruiting to completed.
- 01 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 03 Mar 2015 New trial record